-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Ph+ ALL: New Approaches for Upfront Therapy

Program: Education Program
Session: Adult ALL Advancements: Optimizing Cure in 2024
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Adult, Clinical Research, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024, 2:45 PM-4:00 PM

Marlise R Luskin, MD, MSCE

Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA

Disclosures: Luskin: AbbVie: Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria; KITE: Honoraria; Jazz: Honoraria.

See more of: Adult ALL Advancements: Optimizing Cure in 2024
See more of: Education Program
Previous Presentation | Next Presentation >>